Literature DB >> 8302078

Prospective evaluation of unilateral adrenal masses in patients with operable non-small-cell lung cancer. Impact of magnetic resonance imaging.

M Burt1, R T Heelan, D Coit, P M McCormack, M S Bains, N Martini, V Rusch, R J Ginsberg.   

Abstract

UNLABELLED: We designed a prospective study to evaluate the accuracy of magnetic resonance imaging in distinguishing a benign from a malignant adrenal mass in patients with otherwise operable non-small-cell lung cancer.
METHODS: Potentially operable non-small-cell lung cancer was prospectively staged. If a unilateral adrenal mass was found by computed tomographic scanning, respiratory compensated and cardiac gated thin section magnetic resonance imaging of the adrenal glands was done. One radiologist interpreted the magnetic resonance imaging scan blinded and, on the basis of the relative signal strengths of the T1- and T2-weighted images, judged whether the adrenal mass was benign or malignant. The patients then underwent a percutaneous needle biopsy of the adrenal mass, if technically feasible. If the result of the needle biopsy was nondiagnostic or if the biopsy was not feasible, an adrenalectomy through a posterior approach was performed.
RESULTS: Twenty-seven patients with a unilateral adrenal mass entered the study-11 men and 16 women whose ages ranged from 42 to 75 years (median 58 years). Four patients had epidermoid and 23 adenocarcinoma of the lung. The clinical locoregional stage was I in 9, II in 1, IIIA in 16, and IIIB in 1. Twenty-five completed the magnetic resonance imaging procedure. Five adrenal masses (19%) were metastatic non-small-cell lung cancer (adenocarcinoma = 4, epidermoid = 1); 22 masses (81%) were benign (adenoma = 20, hyperplasia = 2). There were no significant differences in age, sex, histologic type, or locoregional stage between those with a benign versus a malignant mass. However, the malignant masses were significantly larger (3.8 +/- 1.9 cm; range 2.5 to 7.1; median 3.1) than the benign masses (2.0 +/- 0.4 cm, range 1.2 to 2.8; median 2.0) (p < 0.001). Among those having magnetic resonance imaging (n = 25), the technique correctly predicted a malignant mass in the four patients with a histologically confirmed metastasis from non-small-cell lung cancer. However, among the 21 histologically benign masses, the magnetic resonance imaging was interpreted as benign in 5, malignant in 14, and indeterminate in 2. Therefore, although the false-negative rate was 0%, the false-positive rate was 67%.
CONCLUSION: Most adrenal masses in patients with otherwise operable non-small-cell lung cancer are benign. Currently available magnetic resonance imaging methods cannot replace biopsy.

Entities:  

Mesh:

Year:  1994        PMID: 8302078

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  12 in total

1.  PET-CT in the staging and treatment of non-small-cell lung cancer.

Authors:  Patricia Ibeas; Blanca Cantos; José Manuel Gasent; Begoña Rodríguez; Mariano Provencio
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

Review 2.  Staging for M disease.

Authors:  T L Winton
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

3.  A case of synchronous presentation of primary non-small cell lung carcinoma and pheochromocytoma.

Authors:  Jung Wan Han; Cheol-Hong Kim; Juah Jang; Hun Gu Lee; Doo Cheol Chung; Jung Eun Choi; Kwangtaek Kim; Ah Leum Lim; Won Jun Song; Yong Keun Song; Heungjeong Woo; In Gyu Hyun; Mi Kyung Shin; Yong Seong Lee; Ho-Seung Shin
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-04-30

Review 4.  Fluorodeoxyglucose-positron-emission tomography/computed tomography imaging for adrenal masses in patients with lung cancer: review and diagnostic algorithm.

Authors:  W Zachary Stone; David C Wymer; Benjamin K Canales
Journal:  J Endourol       Date:  2013-10-09       Impact factor: 2.942

5.  Performance characteristics of EUS-FNA biopsy for adrenal lesions: A meta-analysis.

Authors:  Suhag Patel; Raxitkumar Jinjuvadia; Anupama Devara; Paul H Naylor; Mohammad Anees; Kartikkumar Jinjuvadia; Mohammad Al-Haddad
Journal:  Endosc Ultrasound       Date:  2019 May-Jun       Impact factor: 5.628

6.  Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer.

Authors:  Masayuki Shirasawa; Tomoya Fukui; Seiichiro Kusuhara; Shinya Harada; Noriko Nishinarita; Yasuhiro Hiyoshi; Mikiko Ishihara; Masashi Kasajima; Satoshi Igawa; Masanori Yokoba; Hisashi Mitsufuji; Masaru Kubota; Masato Katagiri; Jiichiro Sasaki; Katsuhiko Naoki
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

7.  Combined robotic lobectomy and adrenalectomy for lung cancer and solitary adrenal metastasis.

Authors:  Bertram Yuh; Clayton Lau; Kemp Kernstine
Journal:  JSLS       Date:  2012 Jan-Mar       Impact factor: 2.172

8.  (18)F-FDG PET versus (18)F-FDG PET/CT for adrenal gland lesion characterization: a comparison of diagnostic efficacy in lung cancer patients.

Authors:  Yon Mi Sung; Kyung Soo Lee; Byung Tae Kim; Joon Young Choi; Myung Jin Chung; Young Mog Shim; Chin A Yi; Tae Sung Kim
Journal:  Korean J Radiol       Date:  2008 Jan-Feb       Impact factor: 3.500

Review 9.  MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis.

Authors:  Jacqueline Dinnes; Irina Bancos; Lavinia Ferrante di Ruffano; Vasileios Chortis; Clare Davenport; Susan Bayliss; Anju Sahdev; Peter Guest; Martin Fassnacht; Jonathan J Deeks; Wiebke Arlt
Journal:  Eur J Endocrinol       Date:  2016-06-02       Impact factor: 6.664

10.  Are There Any Additional Benefits to Performing Positron Emission Tomography/Computed Tomography Scans and Brain Magnetic Resonance Imaging on Patients with Ground-Glass Nodules Prior to Surgery?

Authors:  Jae Uk Song; Junwhi Song; Kyung Jong Lee; Hojoong Kim; O Jung Kwon; Joon Young Choi; Jhingook Kim; Joungho Han; Sang Won Um
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.